ONO Pharmaceutical Co., Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Gyo Sagara
- Full Time Employees
- 4,206
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 8-2, Kyutaromachi 1-chome Osaka OS Japan 541-8564
- IPO Date
- Jan 1, 1962
- Website
- ono.co.jp
- Similar Companies
- Business
- Ono Pharmaceutical Co., Ltd. (4528.T) develops, manufactures, markets and distributes prescription pharmaceuticals and diagnostic reagents worldwide, with a focus on oncology, immunology, neurology, and pain management; its main products include OPDIVO intravenous infusions for malignant tumors, KYPROLIS for multiple myeloma, EMEND capsules and PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting, DEMSER capsules for pheochromocytoma, BRAFTOVI capsules, MEKTOVI, VELEXBRU and ADLUMIZ tablets for cancers, Orencia injections for rheumatoid arthritis, RIVASTACH patches for Alzheimer's disease, ONGENTYS tablets for Parkinson's disease, PARSABIV intravenous injection for dialysis patients, STAYBLA tablets for overactive bladder, ONON capsules and dry syrups for bronchial asthma and allergic rhinitis, JOYCLU intra-articular injection for joint function, RECALBON tablets for osteoporosis, Glactiv tablets for type 2 diabetes, Forxiga tablets for diabetes, chronic heart failure and chronic kidney disease, Onoact intravenous infusion for tachyarrhythmia, Opalmon tablets for peripheral circulatory disorder, and Coralan for chronic heart failure. Founded in 1717 and headquartered in Osaka, Japan, the company operates primarily in Japan, the United States, Europe and Asia, targeting physicians, hospitals and pharmacies with innovative therapies addressing unmet medical needs. Recent developments include the $2.4 billion acquisition of Deciphera Pharmaceuticals completed in June 2024, adding Qinlock (ripretinib) for gastrointestinal stromal tumors and ROMVIMZA (vimseltinib) for tenosynovial giant cell tumor with subsequent FDA full approval in February 2025 and European Commission approval in September 2025; a strategic collaboration with Vertex Pharmaceuticals in June 2025 to develop and commercialize povetacicept for IgA nephropathy and primary membranous nephropathy in Japan and South Korea; co-development and marketing agreement with Seikagaku Corporation in August 2025 for Gel-One osteoarthritis treatment in Japan; supplemental approval in November 2025 for BRAFTOVI combination therapy in colorectal cancer; research collaborations with PRISM BioLab in April 2024, Jorna Therapeutics in April 2025 and Reborna Biosciences in March 2025 for novel therapeutics; reorganization of US and Europe operations in February 2025; and submission for cenobamate approval in Japan in September 2025.
Company News
Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Down – Time to Sell?
Ono Pharmaceutical Co. (OPHLF) Soars 13.9%: Is Further Upside Left in the Stock?
Reviewing Iterum Therapeutics (NASDAQ:ITRM) and Ono Pharmaceutical (OTCMKTS:OPHLF)
Ono Pharma Enters into a Drug Discovery Partnership with Aitia in Neurological Diseases
Are Investors Undervaluing Ono Pharmaceutical Co. (OPHLF) Right Now?
Ono Pharmaceutical Co. (OPHLF) Q1 Earnings and Revenues Top Estimates
Earnings Preview: Ono Pharmaceutical Co. (OPHLF) Q1 Earnings Expected to Decline
Strength Seen in Ono Pharmaceutical Co. (OPHLF): Can Its 9.2% Jump Turn into More Strength?
Should Value Investors Buy Ono Pharmaceutical Co. (OPHLF) Stock?
Ono Pharmaceutical Co. (OPHLF) Moves 10.4% Higher: Will This Strength Last?
Ono Pharma Announces Oral Presentation of New Data from the Phase 2 Clinical Study of ONO-4578 (EP4 antagonist) in Certain Gastric Cancers at the ASCO 2026 Annual Meeting
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL
Ono Pharmaceutical Co., Ltd. (OPHLY) Presents at 44th Annual J.P.
Ono Pharmaceutical Co., Ltd. (OPHLF) Q1 FY2025 Earnings Call Transcript
Ono Pharmaceutical Co., Ltd. (OPHLF) Q1 2024 Earnings Call Transcript
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
ONO to buy Deciphera Pharmaceuticals at a huge premium
ONO to buy Deciphera Pharmaceuticals at a huge premium
Deciphera Catapults 72% After Ono Pharmaceutical Agrees To Buy It For $2.4 Billion